ANN ARBOR, Mich., October 12, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has filed for an expanded investment license for its production subsidiary, Prodigy Silk. The filing adds capital for the next phase of growth in recombinant spider silk production. Over the last two years, Kraig Labs has significantly expanded its ability to produce spider silk; now it is funding additional scale.
Prodigy Silk is Kraig Labs’ production arm, a vertically integrated operation that rears, harvests, and processes recombinant spider silk. The additional capital will support new capacity, strengthen infrastructure, and push spider silk output higher.
2026 has been a breakout year. In April, the Company delivered a fivefold jump over its previous production high. In June, it set a world record of nearly 2.5 metric tons of spider silk cocoons in a single cycle. In August, it grew output by more than 30% beyond that record, right through the most demanding season of the year. Each result built on the last.
Behind those numbers is a production system designed for success from the ground up. Three rearing centers now operate in parallel. Expanded mulberry cultivation supports them. Redundancy and resiliency are integrated at every level. The system performs as it grows.
“This year, we brought three rearing centers into full operation and set a series of world records in spider silk production,” said Kim Thompson, Founder and CEO of Kraig Labs. “We have proven we can produce, we have proven the system holds up under pressure, and we have delivered recombinant spider silk to industry. This expanded license funds the growth Prodigy Silk will need to address the expected market demand.”
The expansion further confirms that Kraig Labs has moved from production milestones to commercial delivery. The Company shipped its first custom spider silk yarn for a performance sportswear application. Commercial opportunities start with reliable supply. This filing is designed to ensure that Prodigy Silk is ready to scale with market demand.
“Spider silk is moving from a scientific breakthrough to a commercial material,” Thompson continued. “Prodigy Silk is the engine behind that shift. This expanded license is how we will scale that engine to meet the market.”
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Phased Production Model with Staggered Rearing Schedules Keeps Operations Running Continuously, Positioning Kraig Labs to Meet Future Commercial Demand
ANN ARBOR, Mich., October 5, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that its September/October production cycle is well underway, with all three production centers running. Early reports indicate the Company is on track for another successful rearing cycle.
The announcement comes just days after Kraig Labs fulfilled its first purchase order from the performance sportswear segment, shipping custom recombinant spider silk yarn to a globally recognized brand. That delivery marked the Company’s transition from production milestones to commercial deliveries. This last cycle is further evidence of the production engine behind that milestone. Kraig Labs has built a reliable production platform capable of sustaining commercial-scale levels of spider silk to the market.
“Our team in Vietnam is executing well, and the early indicators for this cycle are encouraging,” said Kim Thompson, Founder and CEO of Kraig Labs. “All three centers are up and running on schedule. That matters now, more than ever. We are no longer producing to demonstrate and confirm scale. Production is now focused on addressing the commercial market opportunities for spider silk.”
Kraig Labs uses genetically engineered silkworms to produce silk containing key spider silk proteins. A “rearing cycle” involves raising a batch of silkworms from hatching through cocoon formation. The current cycle focuses on the Company’s parental strains, which are the breeding lines used to produce hybrid silkworm eggs. Silkworms hatched from those eggs subsequently produce the silk cocoons that are processed into yarn.
“Running three centers on phased schedules isn’t just about volume,” Thompson continued. “It’s about building an operation that is resilient at high volume. One center can be in early rearing while another is deep into production and a third is preparing for harvest. That overlap gives us continuous output and real redundancy. If one center faces a disruption, the other two keep moving.”
Kraig Labs’ three production centers each run their own rearing cycle on a staggered schedule, so the facilities are at different stages of development at any given time. This approach maintains a steady supply of hybrid eggs for subsequent silk production while reducing reliance on any single facility.
That redundancy has taken on added significance following the Company’s last production run. Kraig Labs grew silk production by more than 30% through the rainy season, historically one of the most difficult stretches of the year. Management believes the phased model was a key factor behind that result. This system continues to elevate Kraig’s operations with a growing supply line of spider silk available to address opportunities for additional commercial orders.
Thompson concluded, “A continuous, redundant production model is what positions Kraig Labs to move quickly when new opportunities arise. Three centers, three schedules, one continuous operation, prepared for the opportunities ahead.”
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Milestone Marks Recombinant Spider Silk’s Move from Scaled Production to a First-of-Its-Kind Performance Textile
ANN ARBOR, Mich., September 29, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the shipment of its first commercial order of recombinant spider silk yarn. The custom-engineered yarn was produced to fulfill a purchase commitment from a globally recognized performance sports brand and is slated for development into a first-of-its-kind performance textile.
This spider silk sale is part of a confidential pilot development program. The program targets one of the most demanding and innovation-focused segments of the athletic apparel market. The yarn has been custom processed to the customer’s specifications and has now shipped.
“Completing the delivery of this spider silk yarn is a huge milestone for Kraig Labs,” said Kim Thompson, Founder and CEO of Kraig Labs. “The volume is small by design. This is a precision application, not a bulk order. It is exactly the kind of application where spider silk’s real advantages can be highlighted. Strength, flexibility, toughness, and light weight, under conditions pushing materials to their limits. This application is a shining example of how spider silk can transform markets.”
The shipment comes at a pivotal moment for the global textile industry, as fashion and performance brands explore new materials while confronting the challenge of moving promising fiber technologies from laboratory innovation to reliable production. Textile Exchange’s Materials Market Report 2026, published September 22, reported that global fiber production reached a record 139 million metric tons in 2025, with polyester accounting for 59% of total output and 88% of polyester production coming from virgin fossil-based sources. Against that backdrop, the opportunity for emerging performance materials is significant, but so is the challenge: new fibers must deliver differentiated properties while proving they can be produced consistently and integrated into an industry built around enormous volumes of established materials. Kraig Labs’ first commercial shipment represents an important step from material innovation and scaled production toward real-world textile adoption.
Kraig Labs views elite performance apparel as one of the clearest proving grounds for recombinant spider silk. A category where gains in strength-to-weight ratio and durability translate directly into competitive advantage for the athlete.
“High-performance sport is where materials prove themselves,” Thompson continued. “Performance wins. That is the only thing that matters in elite sport. It’s about how it performs when everything is on the line, and that’s exactly what we intend to prove.”
While the quantity of silk in this shipment is small, Kraig Labs believes the true significance lies in what it represents for the broader athletic and performance textile market. A successful application here demonstrates that recombinant spider silk can meet the exacting technical standards of elite sport, standards few materials, natural or synthetic, are able to satisfy. A validated performance application of this kind opens the door to further engagement with brands across the performance apparel space.
“This is the kind of project that changes the conversation,” Thompson concluded. “When a brand at this level puts our material to the test, the results speak for themselves. We intend for this to be the first of many.”
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
ANN ARBOR, Mich., September 24, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced a major milestone for Project Atlas, the Company’s most ambitious genetic engineering initiative to date. The Company has successfully integrated every planned Project Atlas transgene into living commercial silkworm hosts. This milestone completes the foundational Atlas Gene Library for construction of numerous unique recombinant spider silks.
This milestone represents a major breakthrough for the Company’s molecular biology research, genetic engineering, and development. With the Atlas Gene Library now assembled, the Company has entered the next stage of the program focused on developing stable homozygous breeding lines for each Atlas transgene. Project Atlas was designed for specific enhanced properties in strength, toughness, and flexibility that go far beyond the Company’s current production line of recombinant spider silk.
Establishing homozygous Atlas lines will provide the foundation for the systematic creation and evaluation of more than 200 potential genetic pairing configurations, potentially resulting in more than 200 distinct exotic fibers.
These combinations will allow researchers to systematically study how individual Atlas technologies perform together and identify the most promising configurations for future development. With more than 200 unique gene combinations, the Company will have an extensive palette of design configurations from which to engineer exotic fibers with novel and cutting-edge material properties. The objective of Project Atlas is the creation of next-generation recombinant silkworm strains with advanced properties, incorporating the complete suite of Atlas genetics.
“Completing the Atlas Gene Library is a defining milestone for Project Atlas,” said Dr. Xiaoli Zhang, Chief Scientist of Kraig Labs.” Every planned Atlas transgene has now been established in commercial silkworm hosts, giving us the complete set of genetic building blocks we envisioned when Project Atlas began. Our focus now shifts toward developing homozygous breeding lines and systematic evaluation of the more than 200 possible genetic configurations this library enables. Each step builds upon the last, bringing us closer to understanding the full potential of these technologies.”
Project Atlas is a comprehensive genetic engineering initiative capable of combining multiple advanced genetic technologies. It goes far beyond conventional transgenic development efforts that typically focus on individual genetic improvements. The Atlas Gene Library provides the foundation for evaluating how these individual technologies can be assembled into increasingly sophisticated multi-gene recombinant silkworm strains.
The Company believes Project Atlas represents one of the most ambitious genetic engineering initiatives ever undertaken anywhere. Through its Gene Library, Atlas offers more than 200 possible genetic configurations and its ultimate objective: combining the full suite of genes into a single production strain, with unprecedented and targeted material performance characteristics.
As homozygous Atlas lines are established, Kraig Labs will begin systematically creating and evaluating these genetic combinations. This deliberate approach is expected to provide critical insight into how multiple advanced genetic technologies interact and perform together. The knowledge gained through this work will guide the development of future recombinant spider silk technologies and identify the highest-value combinations for future commercial applications.
Project Atlas continues to advance alongside the Company’s expanding commercial spider silk production operations. While Kraig Labs executes its aggressive production scale-up strategy, its research and development team continues building the next generation of recombinant spider silk technologies. By advancing commercialization and innovation in parallel, the Company is building both the manufacturing capacity and scientific foundation needed to support long-term growth.
Completion of the Atlas Gene Library marks the beginning of the next phase of Project Atlas. As additional homozygous lines are established and new genetic combinations are evaluated, the Company expects Project Atlas to continue expanding the performance, versatility, and commercial potential of recombinant spider silk.
Kraig Labs believes the successful completion of the Atlas Gene Library further strengthens its leadership position in advanced biomaterials and genetic engineering, creating a foundation for continued innovation and future commercial opportunities.
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Fashion industry shift puts new focus on bio-based and innovative textiles as Kraig Labs scales recombinant spider silk for potential luxury and performance applications
ANN ARBOR, Mich., September 14, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today highlighted the growing opportunity for advanced biomaterials in fashion as New York Fashion Week begins.
The Council of Fashion Designers of America (CFDA) has pointed to bio-based materials, innovative fibers and new approaches to textile development as an important part of the evolving fashion landscape.
For Kraig Labs, the shift reflects a broader transformation already taking place across fashion: innovation is increasingly occurring not only in how clothing is designed, but in what it is made from.
“Some of the most exciting innovation in fashion today is happening at the material level,” said Kim Thompson, founder and CEO of Kraig Labs. “As designers explore new possibilities beyond conventional fibers, we believe spider silk will offer an entirely new combination of lightweight, beauty, and performance.”
Interest in next-generation materials has accelerated across the global fashion industry, with leading designers and luxury houses experimenting with bioengineered fibers, plant-based materials, and other novel textiles. Spider silk, long studied for its exceptional mechanical properties, has begun the transition from scientific research to fashion applications.
Kraig Labs has made major progress in addressing one of the central challenges facing emerging biomaterials: scale.
Unlike approaches that produce silk proteins through fermentation followed by additional processing to create usable fibers, Kraig Labs uses genetically engineered silkworms to produce recombinant spider silk directly. The Company’s production model is designed to leverage the infrastructure, expertise, and processing systems already established by the global silk industry.
Earlier this year, Kraig Labs reported the production of approximately 3.2 metric tons of recombinant spider silk cocoons in a single production cycle, a world record, and those numbers are expected to go higher.
“The challenge for advanced materials is not simply demonstrating what is scientifically possible,” Thompson continued. “To have a meaningful impact on industries like fashion and performance textiles, they must ultimately be manufactured efficiently, consistently, and at commercial scale. That is the challenge Kraig Labs is solving.”
As fashion enters a new era of material experimentation, Kraig Labs believes recombinant spider silk will provide designers and textile manufacturers with a new class of high-performance fiber combining the heritage and manufacturing infrastructure of traditional silk with properties inspired by one of nature’s most remarkable materials.
The Company continues to advance production, processing, and commercialization of its recombinant spider silk technologies for potential applications spanning luxury textiles, performance apparel, protective materials, and other advanced-material markets.
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Feature Explores the Real Biology Behind Recombinant Spider Silk and the Scientific Case for Kraig Labs’ Production Platform
ANN ARBOR, Mich., September 3, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today highlighted recent coverage by Tech Times examining the scientific gap between fictional biology and real-world advances in recombinant spider silk production.
This in-depth article addresses a central element in commercializing spider silk. Producing spider silk proteins is only the first step. Engineering a practical biological system that can produce silk at scale is the key driver for broad commercialization. Rather than recreating a spider’s silk-producing anatomy from scratch, Kraig Labs uses the naturally evolved silk-producing machinery of the silkworm. Genetic engineering introduces key spider silk proteins into that existing biological platform.
As the article notes, Kraig Labs uses genetically engineered Bombyx mori silkworms as biological production systems. This model leverages the silkworms’ sophisticated silk glands and spinning architecture.
That distinct strategy sits at the core of Kraig Labs’ technology. The challenge was never proving that spider silk proteins can be produced. It was building a production platform that delivers recombinant spider silk at meaningful scale, with commercially relevant properties.
Kraig Labs recently reported strong progress on that front. On August 24, 2026, the Company announced a new production record, increasing output more than 30% above its previous milestone. The achievement stood out for another reason. It came during the rainy season, one of the most technically demanding stretches of the Company’s production calendar.
The Tech Times feature offers a compelling lens on that progress. By explaining why fictional wrist spinnerets are biologically implausible, and how transgenic silkworms offer a scientifically credible path to commercial spider silk production. The article places Kraig Labs’ technology within the broader history of spider silk research and its leading role in its commercialization.
“We appreciate Tech Times for bringing this level of scientific depth to the conversation around spider silk. This article captures exactly what we set out to build,” said Kim Thompson, Founder and CEO of Kraig Biocraft Laboratories. “We took a proven biological system and gave it a new purpose. That work is now producing real silk, at real scale, moving toward real commercial applications.”
Thompson added, “The distinction between producing spider silk proteins and reproducing the biological machinery that spins them is exactly what our technology does. This article highlights what we’ve known all along; the key to unlocking spider silk’s commercial potential was a cost-effective and scalable production platform.”
Kraig Labs’ technology is built around a genetically engineered silkworm that produces recombinant spider silk. From single grams to metric tons, the Company has turned a scientific breakthrough into a functioning production platform.
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Tech Times
Tech Times goes beyond the announcement to examine the science, technology, business dynamics, and real-world implications behind the developments shaping tomorrow. While traditional coverage often focuses on the headline moment—a product launch, funding round, research result, or corporate announcement—Tech Times explores what comes before and after, following the research, technical decisions, competitive forces, and second-order consequences that determine where a story ultimately leads. Its cross-disciplinary approach reflects how STEM actually works, recognizing that advances in science, healthcare, materials, computing, and business increasingly intersect. Tech Times is committed to precision, depth, and context, providing coverage that is useful to practitioners while remaining accessible to anyone driven by genuine curiosity. Owned and operated by Tech Times Media Inc., headquartered in New York City with newsrooms across the United States, Europe, and Asia, Tech Times is independently operated and editorially driven, with sponsored content clearly identified.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Company Achieves Record Growth Through Peak Rainy Season, with Management Confirming Even Greater Output Within Reach
ANN ARBOR, Mich., August 24, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has set another spider silk production record, increasing output by more than 30% over its previous record-setting levels. The milestone marks the Company’s latest breakthrough, in a year defined by record achievements, and it comes with an added distinction. This cycle was completed during the rainy season, widely regarded as the most technically demanding stretch of the year for silk production.
Rainy season conditions have long posed one of the toughest operational challenges in sericulture, affecting everything from rearing environment stability to mulberry feedstock handling. Many producers see output slow considerably during this period. Kraig Labs did the opposite. The Company grew production by more than 30%, right through the most difficult production window of the year.
“Growing production by more than 30% is a major achievement on its own. Doing it during rainy season shows just how far our operations have come,” said Kim Thompson, Founder and CEO of Kraig Labs.
Management noted that the result is even more significant given a real operational constraint the Company managed throughout the cycle. Mulberry leaves must be harvested and fed while they are dry; rainy season conditions make this far more difficult. That constraint limited usable mulberry feedstock considerably during the cycle. Kraig Labs confirmed that its rearing capacity was positioned to deliver an even larger increase had more usable mulberry been available.
“Producing high volumes in the rainy season definitely added challenges, but we embraced it as an opportunity to stress-test our system,” Thompson added.” As a result, we identified access to additional mulberry as a key factor for increased production.”
To capture that opportunity, Kraig’s operations team is now working to secure additional land dedicated to expanding the Company’s in-house mulberry production capacity.
“We move fast when we see an opportunity to grow,” Thompson stated. “Securing more land for mulberry production is already underway, and we expect that capacity to be online within the next two to three months. When it comes online, we expect to see another significant boost in spider silk production.”
The Company also pointed to a broader operational shift behind this cycle’s success. With multiple rearing operations now running in parallel, Kraig Labs has moved beyond producing in isolated, defined batches. Production has transitioned into a continuous rolling operation. This system delivers steady, ongoing output rather than a series of separate cycles. This critical shift made this cycle’s rainy season performance possible.
“A conventional batch system would have taken this season off. A continuous system doesn’t have that option, and it didn’t need it,” Thompson continued. “This is the operating model of a company built to supply spider silk at commercial scale, in any season, on a rolling basis. That is the business we have built.”
Kraig Labs believes this result, achieved during the most demanding conditions of the year, points directly to the durability and capability of its production platform and business model.
“This is what our operation is built to do,” Thompson concluded. “Growth, in any season, under any conditions, with resiliency and redundancy integrated at every level. Once our expanded mulberry capacity comes online, we expect that growth to accelerate even faster. We are just getting started.”
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Byline Article Introduces “Authored Biology” Framework and Draws on Kraig Labs’ Spider Silk Journey to Chart the Future of Biology-Enabled Manufacturing
ANN ARBOR, Mich., August 10, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that the Company’s CEO and Founder, Kim Thompson, published a thought leadership scientific opinion editorial in Biocompare, a leading publication serving the life sciences and biotechnology research community. The article, titled “Beyond Therapeutics: The Next Chapter of Synthetic Biology Is Manufacturing,” introduces a framework Thompson calls “authored biology” and draws on Kraig Labs’ experience commercializing recombinant spider silk to chart what he sees as the next great opportunity in synthetic biology.
In the piece, Thompson describes a second transformation now taking shape alongside the well-known advances in gene therapy, CRISPR, and precision medicine, one centered on materials, chemicals, and manufacturing rather than treatment.
“Mention genetic engineering today, and most people immediately think of gene therapies, CRISPR, precision medicine, or the next breakthrough drug,” Thompson writes. “But another transformation is quietly taking shape.”
Thompson draws from Kraig Labs’ own history as a case study for the broader industry. He writes that producing a protein in a laboratory and manufacturing a finished material at commercial scale are fundamentally different challenges, a lesson he says defines the road every biology-enabled material must travel.
“Producing spider silk proteins is only part of the challenge,” Thompson writes. “Transforming those proteins into continuous fibers that can be spun into yarn and woven into fabric is an entirely different manufacturing process. It’s the difference between producing a raw material and creating a finished product.”
At the center of the article is the concept of “authored biology,” a term Thompson uses to describe an approach distinct from traditional synthetic biology. Rather than building biological systems entirely from scratch, Thompson argues that some of the greatest opportunities lie in enhancing natural systems that have already been refined over centuries, an approach that reflects Kraig Labs’ own strategy of engineering silkworms rather than replacing them.
“Innovation does not always require replacing natural systems,” Thompson writes. “In many cases, the greatest opportunity lies in combining advances in genetic engineering with biological platforms that have already proven themselves over centuries or even millennia.”
Thompson closes the article by arguing that the industry’s next era of leadership will be defined not by discovery alone, but by the discipline required to scale it.
“The next chapter of synthetic biology won’t be defined by what can be engineered in the laboratory,” Thompson writes. “It will be defined by what can be manufactured consistently, economically, and at scale. That transition, from scientific possibility to commercial reality, may ultimately prove to be the field’s greatest achievement.”
Kraig Labs believes Thompson’s perspective reflects lessons earned directly through the Company’s multi-year effort to scale recombinant spider silk from laboratory quantities to commercial production. The Company views this kind of thought leadership as an important complement to its operational progress, reinforcing Kraig Labs’ position at the forefront of both the science and the strategic thinking shaping the future of biology-enabled manufacturing.
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
What happens when one of the world’s most influential science channels spends the day exploring one of nature’s most extraordinary materials? The answer is Veritasium’s latest spider silk episode. From molecular biology and genetic engineering to large-scale silk production and some unforgettable strength demonstrations, the episode takes viewers behind the scenes at Kraig Biocraft Laboratories for an inside look at how recombinant spider silk is becoming a commercial reality.
ANN ARBOR, Mich., August 3, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced its featured appearance in a new Veritasium episode that takes viewers inside the Company’s recombinant spider silk operations before putting the material to the test in a Spider-Man-inspired strength demonstration.
Veritasium, founded and hosted by Derek Muller, has grown into one of the world’s premier science channels. With more than 20 million subscribers and billions of views, Veritasium has become internationally recognized for exploring science, engineering, and innovation through engaging storytelling, real-world demonstrations, and a commitment to making complex scientific concepts accessible to audiences around the globe.
For this episode, Henry van Dyck, one of Veritasium’s award-winning hosts, visited Kraig Labs, bringing the channel’s signature curiosity and hands-on approach to exploring the science behind commercial recombinant spider silk.
During his visit, Henry spent an entire day with Company’s scientists, engineers, and production experts, learning how Kraig Labs has transformed one of nature’s most extraordinary materials into a scalable commercial technology. From molecular biology and genetic engineering to large-scale production, the visit provided an in-depth look at the science, engineering, and manufacturing behind the commercialization of recombinant spider silk.
After learning about Kraig Labs’ technology and commercial production process, Henry took a sample of the Company’s recombinant spider silk back to the Veritasium team to put the material to the test. At a local climbing gym, Derek, Henry, and members of the Veritasium team highlighted the remarkable strength of silk in a real-world, Spider-Man-inspired demonstration. The team took turns doing their best Spider-Man impressions, suspending themselves from Kraig Labs’ recombinant spider silk.
The extraordinary strength-to-weight characteristics of recombinant spider silk were on full display. Derek provided the audience with an important lesson in materials science: when you create a material strong enough to withstand extreme forces, the material itself may no longer be the weakest link. In this case, the recombinant spider silk remained intact, while the small contact area on his hand where the force was transferred became the limiting factor. The demonstration provided a memorable illustration of the extraordinary strength-to-weight ratios that make spider silk one of nature’s most remarkable materials.
The episode arrives as Spider-Man: Brand New Day opens in theaters, creating a timely opportunity to explore the real-world materials science behind one of popular culture’s most recognizable superpowers.
“It was an absolute pleasure to host Henry and the Veritasium team,” said Jon Rice, COO of Kraig Labs. “Their enthusiasm for science, thoughtful questions, and genuine curiosity made this an unforgettable experience for everyone at Kraig Labs. For decades, spider silk has captured the imagination of scientists, engineers, and the public. Seeing that curiosity translated into a real commercial technology is exactly why opportunities like this are so meaningful. We are incredibly grateful for the time they invested in understanding our technology and for sharing our work with millions of people around the world.”
Dr. Xiaoli Zhang, Chief Scientist of Kraig Labs, added, “Spider silk has fascinated scientists for generations because of its extraordinary properties. It was a pleasure to share the science behind our recombinant spider silk technology and to demonstrate how years of research have enabled commercial production. We sincerely thank the Veritasium team for their endless curiosity, thoughtful questions, and passion for scientific discovery. Opportunities like this help inspire the next generation of scientists while introducing millions of people to the incredible potential of recombinant spider silk.”
The Company’s appearance in Veritasium’s latest spider silk episode represents one of the broadest public introductions yet to recombinant spider silk and Kraig Labs’ pioneering technology. As the Company continues expanding commercial production while advancing next-generation innovations through Project Atlas, opportunities like this help introduce the remarkable potential of recombinant spider silk to audiences around the world.
Kraig Biocraft Laboratories extends its sincere appreciation to Derek, Henry, and the entire Veritasium production team for their professionalism, curiosity, and commitment to making science accessible to everyone. The Company is proud to have shared its laboratories, its scientists, and its vision for the future of commercial spider silk with one of the world’s most respected science channels and its global audience.
About Derek Muller and Veritasium: Making Science Accessible to Millions
Dr. Derek Muller is an award-winning science communicator, filmmaker, educator, and media personality best known as the creator and host of Veritasium, one of the world’s largest and most influential science channels on YouTube. Muller has built a global audience by explaining complex scientific concepts through engaging experiments, expert interviews, and thought-provoking demonstrations that challenge common misconceptions.
Today, Veritasium has grown to 21 million subscribers and nearing 4.5 billion views, making it one of YouTube’s premier destinations for science and educational content. Muller also operates two additional channels: 2veritasium and Sciencium.
Muller’s extensive television career includes; correspondent on Australia’s long-running science program Catalyst, appearance on Bill Nye Saves the World for Netflix, and host of acclaimed documentaries including Uranium – Twisting the Dragon’s Tail, Vitamania: The Sense and Nonsense of Vitamins, Ancient Impossible, and Digits.
Muller’s content covers an exceptionally broad range of scientific disciplines, from physics and engineering to astronomy, mathematics, chemistry, biology, artificial intelligence, and emerging technologies. His contributions to science communication have earned numerous honors, including the 2017 Streamy Award for Best Science and Education Channel, the Eureka Prize for Science Journalism, the Richtmyer Memorial Lecture Award, the Australian Webstream Award, and the 2025 AAAS Kavli Science Journalism Gold Award for his investigation into PFAS contamination. His work has also been featured by publications including Scientific American, Wired, and Gizmodo.
In addition to digital media, Muller has appeared on stage alongside renowned science communicators including Neil deGrasse Tyson, Michio Kaku, and Chris Hadfield, and co-hosted the 2017 March for Science in Washington, D.C. He also launched Snatoms, an educational magnetic molecular modeling kit that exceeded its crowdfunding goal within its first hour and has since become a popular STEM education product.
For more information, visit www.veritasium.com or explore Veritasium’s YouTube channels for hundreds of videos covering some of the most fascinating questions in science and technology.
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Disclaimer
References to Spider-Man are for descriptive and editorial purposes only. Kraig Biocraft Laboratories and Veritasium are not affiliated with, sponsored by, or endorsed by Marvel Entertainment, Sony Pictures Entertainment, or their respective affiliates.
Interview Spotlights Company’s Commercial-Scale Production Progress and Path to Transforming the Global Textile Industry
ANN ARBOR, Mich., July 21, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that CEO and Founder Kim Thompson is featured in an in-depth interview published by Just Style, a leading global trade publication serving the apparel sourcing and textile manufacturing industry. The interview highlights Kraig Labs’ rapid production scale-up, its plug-and-play commercialization strategy, and Thompson’s vision for a biology-enabled future of textile innovation.
Just Style reaches brand executives, sourcing directors, materials innovators, and supply chain decision-makers across the global apparel industry. Coverage in this publication places Kraig Labs directly in front of the commercial partners most relevant to the Company’s near-term commercialization objectives.
In the interview, Thompson described Kraig Labs’ production trajectory in clear, measurable terms. He traced the Company’s output from single grams to kilograms, then hundreds of kilograms, and, most recently, to 2.5 metric tons of recombinant spider silk cocoon early this summer. He also outlined the Company’s next target.
“We set a target for ourselves of 10 metric tonnes of recombinant spider silk cocoon a month,” Thompson told Just Style. “To achieve that this year, in 2026 and maybe within the next 60 days.”
Thompson addressed one of the most important strategic advantages of Kraig Labs’ production model, its compatibility with the global silk industry’s existing infrastructure.
“When I designed this system, it was designed originally to be plug and play,” Thompson said. “We create a transgenic silkworm that is virtually identical in every way except the silk it produces from a mundane silk farm.”
That plug-and-play design is central to Kraig Labs’ commercialization strategy. The Company is not asking the textile industry to rebuild its supply chain. It is offering a material that works within the infrastructure already in place, infrastructure that Thompson noted already produces more than 150,000 metric tons of silk annually.
On market positioning, Thompson was direct. Recombinant spider silk is not a commodity fiber. It is a premium, rare, natural material, unlike anything currently available in the industry.
“In the near term, I think that in high fashion, where the customer is not looking for either disposable fashion, but for true quality and something truly unique and rare, made by nature,” Thompson told Just Style.
The interview also explored the broader vision underpinning Kraig Labs’ long-term strategy. Thompson described a future in which the next generation of textile materials is not engineered in chemical plants but grown on farms, designed in laboratories, and produced through agricultural systems already woven into global supply chains.
Kraig Labs believes this growing recognition from respected global trade publications reflects the Company’s emergence as a serious commercial force in advanced materials. It reinforces the Company’s position at the forefront of recombinant spider silk commercialization and signals expanding awareness among the brand partners and supply chain leaders the Company is actively engaging.
The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
